tetano
Editor, Senior Moderator
JHEP Rep. 2020 Jun;2(3):100113. doi: 10.1016/j.jhepr.2020.100113. Epub 2020 Apr 2.
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.
Boettler T[SUP]1[/SUP], Newsome PN[SUP]2,[/SUP][SUP]3[/SUP], Mondelli MU[SUP]4[/SUP], Maticic M[SUP]5,[/SUP][SUP]6[/SUP], Cordero E[SUP]7[/SUP], Cornberg M[SUP]8,[/SUP][SUP]9[/SUP], Berg T[SUP]10[/SUP].
Author information
Abstract
The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.
? 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
KEYWORDS:
ACE-I, angiotensin-converting enzyme inhibitor; ACE2, angiotensin-converting enzyme 2; ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; EGD, esophagogastroduodenoscopy; ERC, endoscopic retrograde cholangiography; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NUC, nucleoside analogue; PIs, protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ULN, upper limit of normal
PMID:32289115PMCID:PMC7128473DOI:10.1016/j.jhepr.2020.100113
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.
Boettler T[SUP]1[/SUP], Newsome PN[SUP]2,[/SUP][SUP]3[/SUP], Mondelli MU[SUP]4[/SUP], Maticic M[SUP]5,[/SUP][SUP]6[/SUP], Cordero E[SUP]7[/SUP], Cornberg M[SUP]8,[/SUP][SUP]9[/SUP], Berg T[SUP]10[/SUP].
Author information
Abstract
The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.
? 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
KEYWORDS:
ACE-I, angiotensin-converting enzyme inhibitor; ACE2, angiotensin-converting enzyme 2; ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; EGD, esophagogastroduodenoscopy; ERC, endoscopic retrograde cholangiography; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NUC, nucleoside analogue; PIs, protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ULN, upper limit of normal
PMID:32289115PMCID:PMC7128473DOI:10.1016/j.jhepr.2020.100113